Financial Data and Key Metrics Changes - For the fourth quarter, revenue reached $800 million, a 7% increase year-over-year, with adjusted EPS of $3.74, up $0.48 from last year [25][31] - Comparable sales rose 9%, with stores up 9% and direct sales up 8%, marking the strongest quarterly comp performance of the year [26][30] - Adjusted operating income was $56 million for the quarter, an increase of 17% compared to $48 million last year [31] Business Line Data and Key Metrics Changes - Journeys led with a 12% growth in comparable sales, building on a 14% increase in Q4 last year [26] - Johnston & Murphy saw a 2% increase in comps, with sequential improvement in December and January [27] - Schuh's comps rose 3%, driven by holiday promotional activity, with e-commerce penetration exceeding 50% of sales [27] Market Data and Key Metrics Changes - The U.K. retail environment for Schuh remained highly promotional and competitive, resulting in a lackluster holiday season [15] - The footwear market overall saw Journeys outperforming, gaining market share particularly among the youth customer base [13] Company Strategy and Development Direction - The company is focusing on a "Footwear First" strategy, emphasizing customer-centric initiatives and improving cost structures [52][73] - Plans include expanding the 4.0 store format, with an aim to double the number of these stores to enhance customer experience and drive sales [60][104] - The company aims to restore margin discipline at Schuh while prioritizing profitability over short-term comp gains [37][66] Management's Comments on Operating Environment and Future Outlook - The consumer environment remains selective, with demand accelerating during key shopping periods [8] - Management expressed confidence in achieving meaningful earnings opportunities across strategically positioned businesses, despite challenges [22][34] - The company anticipates continued strength at Journeys and improvement at Johnston & Murphy, while Schuh is expected to reset for profitability [34][40] Other Important Information - The company ended the year with a positive net cash position and generated $164 million of free cash flow in the fourth quarter [31][32] - Capital expenditures for the year are expected to be approximately $65 million-$70 million, primarily for store remodels and new openings [47] Q&A Session Summary Question: Performance of Journeys and comp expectations - Management indicated that Journeys is tracking in the mid-single digits for February, with expectations for higher comps in the early part of the year due to tax refunds [80] Question: Changes to the assortment for Journeys - Management noted that growth is expected from existing franchises rather than new brands, with a focus on meeting customer demands [85] Question: Gross margin pressure at Schuh - It was highlighted that about 60% of the gross margin deleverage in 2026 was attributable to Schuh, with expectations for recovery in 2027 [88][89] Question: Timing of store openings and closings - Management confirmed plans to open 80 new 4.0 stores, with closures primarily around lease expirations, predominantly in Q1 and Q2 [105] Question: Sales in licensed businesses - Management expects the most pressure from down sales in the second quarter, with plans to improve gross margins over time [112]

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [24] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [25] - Total cash inflow for the year amounted to $32 million, bolstered by public offerings and the exercise of investor warrants [19][20] Business Line Data and Key Metrics Changes - The EVX-01 program for advanced melanoma showed a high objective response rate of 75% and a complete response rate of 25% based on 2-year phase 2 data [10] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [12] - The EVX-B2 program targeting Neisseria gonorrhoeae retained full global rights, with strong preclinical data indicating significant protection in mouse models [14] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][6] - The autoimmune disease market is characterized by over 14 million patients annually in the U.S., presenting a significant opportunity for the company's platform [7] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [32] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [51] - The company is committed to deriving value from its platform and pipeline assets through partnerships [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [30] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [27] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [60] Other Important Information - The company received recognition from the Galien Foundation for its AI advances in human health [5] - The automated vaccine design module launched in October 2025 enhances the design cycle, reducing costs and development time [18] Q&A Session Summary Question: Changes to strategy under new CEO - The CEO noted that the fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [30] Question: Regulatory submission for EVX-04 - The CEO indicated that while initial proof of concept is important, further validation data will strengthen the value proposition for external partners [34] Question: Partnering efforts for EVX-01 - The CEO mentioned that strong clinical data and translational insights are key to driving interest from potential partners [41] Question: Autoimmune disease strategy - The company is analyzing prevalent autoimmune diseases to identify suitable indications for its platform [72]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue reached $800 million, a 7% increase year-over-year, with comparable sales rising 9% [16] - Adjusted EPS for the quarter was $3.74, up $0.48 from the previous year, while full-year adjusted EPS was $1.45, compared to $0.94 last year [15][19] - Adjusted operating income for the quarter was $56 million, a 17% increase from $48 million last year [19] Business Line Data and Key Metrics Changes - Journeys led the growth with a 12% increase in comparable sales, building on a 14% increase in the same quarter last year [16] - Johnston & Murphy saw a 2% increase in comparable sales, with improvements noted in December and January [17] - Schuh's comparable sales rose 3%, driven by holiday promotions, but faced challenges due to a highly promotional environment [17] Market Data and Key Metrics Changes - E-commerce penetration at Schuh exceeded 50% of sales, reflecting a shift towards online shopping in a promotional market [17] - The U.K. retail environment remained competitive and promotional, impacting Schuh's profitability during the holiday season [10] Company Strategy and Development Direction - The company is focusing on a "Footwear First" strategy, emphasizing customer-centric initiatives and improving cost structures [31][32] - Plans for Journeys include expanding the 4.0 store format, enhancing product assortments, and increasing brand awareness through marketing campaigns [36][35] - Schuh aims to improve profitability by reducing reliance on discounting and enhancing product offerings [39] Management's Comments on Operating Environment and Future Outlook - The consumer environment is described as selective, with demand peaking during key shopping periods [5] - Management expressed confidence in achieving growth despite external challenges, with a focus on evolving product offerings to meet changing consumer needs [13][14] - The company anticipates a flat sales outlook for fiscal 2027, with expected comparable sales growth of 1%-2% [22] Other Important Information - The company ended the year with a positive net cash position and generated $164 million in free cash flow during the fourth quarter [19][20] - Capital expenditures for the year are projected to be between $65 million and $70 million, primarily for store remodels and new openings [28] Q&A Session Summary Question: How is the Journeys business performing quarter to date? - Management reported mid-single-digit growth for Journeys in February, with expectations for higher comps in the early part of the year due to anticipated tax refunds [43][46] Question: Can you discuss changes to the assortment for Journeys? - The company is focusing on existing franchises for growth rather than solely adding new brands, with continued success expected from brands like Hoka and Nike [48][50] Question: How much pressure did Schuh face on gross margin in 2026? - Approximately 250 basis points of gross margin pressure was attributed to Schuh, with expectations for recovery in 2027 as promotional activities are reduced [51][54] Question: What is the timing for store openings and closures? - The company plans to open 80 new 4.0 stores this year, with closures primarily occurring around lease expirations [65][67] Question: How will the licensed businesses perform in the first half of the year? - The company expects significant pressure from licensed business sales, particularly in the second and third quarters, with plans to improve gross margins over time [72][74]

Financial Data and Key Metrics Changes - The company reported full-year GAAP net earnings of $208 million for 2025, a significant increase from $54.8 million in 2024 [19] - Full-year adjusted net earnings were $258.8 million, up approximately 17% from $221.6 million in 2024 [19] - Full-year net earnings per share (EPS) was $0.27, with adjusted net EPS of $0.34, exceeding guidance by $0.02 [5][22] - Operating expenses as a percentage of gross revenue decreased from approximately 38% in 2024 to roughly 36% in 2025 [6] Business Line Data and Key Metrics Changes - The increase in adjusted net earnings was primarily driven by $10.3 million from new utility rates implemented across various systems [20] - New utility rates contributed $41.6 million of benefit from approved rate implementations throughout the year [22] - The regulated services group growth was supported by new rate implementations, favorable weather, and lower interest expenses [24] Market Data and Key Metrics Changes - The company operates in high-quality jurisdictions with attractive regulatory mechanisms, including tracker mechanisms and multi-year rate plans [16] - Recent legislative and regulatory developments in states like Missouri and Arizona are enhancing investment recovery [17] Company Strategy and Development Direction - The company aims to become a premium pure-play regulated utility, focusing on operational discipline and regulatory strategy execution [5][10] - A centralized capital projects team is being implemented to improve execution and performance [9] - The capital expenditure outlook for 2026-2028 is approximately $3.2 billion, with a focus on safety, reliability, and service improvements [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 earnings guidance, reaffirming the adjusted net EPS estimate in the range of $0.35-$0.37 [30] - The effective tax rate for 2027 is now expected to be in the mid-to-high 20% range, impacting future earnings projections [11][30] - Management emphasized the importance of operational excellence and regulatory engagement to drive sustainable earnings growth [32] Other Important Information - The company strengthened its balance sheet by using net proceeds from the sale of its renewable business to retire approximately $1.6 billion of debt [7][27] - Total debt stands at approximately $6.5 billion, with a solid investment-grade credit rating [28] Q&A Session Summary Question: What are the largest drivers behind the revised 2027 guidance? - The effective tax rate moved from low to mid-twenties to mid to high twenties, resulting in a deduction of about $0.03 per share in EPS [36] Question: What are the largest levers the business can pull in the near term? - The focus is on regulatory engagement and leveraging a strong balance sheet to pursue organic growth opportunities [38] Question: Can you provide an update on the additional opportunities mentioned? - The growth story starts with organic growth within existing jurisdictions, with a disciplined approach to potential M&A opportunities [46] Question: How is the company progressing on customer metrics for the Missouri rate case? - The company believes it has satisfied the customer metrics and is in the process of validating this with the commission [96]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported net income of $14.8 million and diluted earnings per share of $1.03, with a GAAP net combined ratio of 64.2 and an annualized return on equity of 51% [4][17] - For the full year, net income more than doubled to $40.8 million, and diluted earnings per share increased by 95% to $2.88, with a return on equity of 43% [4][17] - The underlying combined ratio improved to 74.4 in 2025 from 79.5 in 2024, reflecting structural improvements in operations [11][21] Business Line Data and Key Metrics Changes - Direct premiums written grew 14% in Q4 to $82.8 million and 15% for the full year to $277.8 million, driven by higher average premiums and strong retention [6][17] - The Select product now represents 57% of policies in force, up from 45% a year ago, contributing to improved risk selection and lower claims frequency [5][6] Market Data and Key Metrics Changes - The company plans to enter the California market in Q2 2026, which is expected to become a significant contributor to growth over time [9][10] - The California homeowners market is valued at $15 billion, nearly double that of New York, with a growing supply-demand imbalance for homeowners coverage [9] Company Strategy and Development Direction - The company aims to achieve $500 million in direct premiums written by year-end 2029, focusing on growth in New York and measured expansion into new markets [9][12] - The strategy includes maintaining underwriting discipline and not chasing volume at the expense of risk management [6][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic direction and ability to navigate competitive pressures in New York, emphasizing strong producer relationships and operational efficiency [16][45] - The guidance for 2026 includes direct premiums written growth of 16%-20% and an underlying combined ratio of 74%-76%, with expectations of higher catastrophe losses [12][22] Other Important Information - The company has no debt and reported shareholder equity of $122.7 million, an increase of 84% during the year [24] - The expense ratio improved to 30% in 2025, down from 41% in 2021, marking a significant milestone for the company [21] Q&A Session Summary Question: Differences in California Risks - Management highlighted that California is a large, dislocated market and will use the Select product tailored for California's unique risks, particularly wildfire [30][31] Question: Quota Share for California Business - The company will start with a 30% quota share for California to manage risk effectively [33] Question: Expense Ratio Projections - Management indicated that the expense ratio could potentially decrease further to the 29%-30% range, reflecting economies of scale [41] Question: Competition in New York - Management noted that while competition is increasing, the company has maintained its execution and competitive advantages in the market [45]

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses for 2025 were $148 million, lower than in 2024 due to many late-stage trials nearing completion [6] - Cash position strengthened to approximately $1.4 billion, allowing for accelerated global development and exploration of in-licensing and M&A opportunities [4][7] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and SULANDA accounted for 11% of total 2025 in-market sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting overall performance [9] - China sales under the brand name ELUNATE experienced a -13% decline in the first half but rebounded with 33% growth in the second half [9] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing an addressable market of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of ATTC programs while exploring business development opportunities [25] - Focus on expanding the hematology portfolio with new products and establishing a dedicated sales and marketing team for this specialized area [11][71] - The strategy includes potential partnerships for the ATTC platform to validate and enhance its value [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with oncology revenue guidance set between $330 million and $450 million, reflecting strong growth expectations [7][25] - The company anticipates continued growth from new indications and the global expansion of FRUZAQLA [31] - Management highlighted the importance of maintaining a balance between existing commercial products and emerging opportunities from the ATTC platform [52] Other Important Information - The company has advanced two ATTC programs into clinical trials, with significant market potential anticipated [4] - The SAFFRON and SANOVO readouts are expected in mid-2026, which are critical for future growth [31][24] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and continued recovery in sales [30][31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [31][36] Question: Can you provide details on the ATTC platform candidates? - A251 is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [31] Question: How are commercial dynamics expected to stabilize in 2026? - Management noted that turnover rates have decreased and the sales team has been restructured to focus on top-tier hospitals, which should improve performance [41][42] Question: What is the impact of MET testing adoption on savolitinib? - No additional information was provided on the influence of MET testing adoption on savolitinib uptake [48] Question: What is the partnering strategy for the ATTC platform? - The company is considering licensing out some programs while maintaining control over others to maximize long-term value [50] Question: What is the guidance for R&D expenses this year? - Management indicated a desire to ramp up R&D investment to a range of $250 million to $300 million [60] Question: Can you elaborate on the in-licensing and M&A strategy? - The company is open to in-licensing late-stage commercial assets or complementary assets, given its strong cash position [63] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [71]

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses decreased to $148 million in 2025, lower than in 2024 due to many late-stage trials nearing completion [6] Business Line Data and Key Metrics Changes - Ex-China sales of FRUZAQLA grew by 26% year-over-year, reaching $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and Surufatinib accounted for 11% of total EMARC sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting growth [9] - China sales under the brand name ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [9] - The ITP market in China is significant, with over 250,000 actively treated patients, representing a market potential of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [4][26] - Focus on building a strong hematology portfolio, with the first-in-class treatment for EZH2 mutation approved [11] - The company is pursuing partnerships with multinational companies to validate and add value to its ATTC platform [48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [26] - The oncology revenue guidance for 2026 is projected to be between $330 million and $450 million, reflecting strong growth expectations [7][26] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [71] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated development and exploration of business opportunities [4] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20][21] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong momentum and growth from new indications, with expectations for continued recovery [31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [32] Question: Can you provide details on the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2-expressing solid tumor patients, focusing on post-HER2 treatment settings [32] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that the impact from Medicare changes has already been reflected in 2025 results, but they anticipate continued growth in ex-U.S. markets [71] Question: What is the strategy for partnering with the ATTC program? - The company is open to licensing out some programs to accelerate development while maintaining control over others for long-term value [48] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [69]

Financial Data and Key Metrics Changes - The company reported a revenue of $366 million for the period, reflecting a 26% increase compared to the previous year [1]. Business Line Data and Key Metrics Changes - Specific business line performance details were not provided in the available content, indicating a lack of clarity on individual segment contributions [5]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were mentioned in the provided content [5]. Company Strategy and Development Direction - The company is focusing on first-in-class products and has several NDA submissions planned for 2025 and 2026, indicating a strong pipeline and commitment to innovation [2][4]. Management Comments on Operating Environment and Future Outlook - Management has not provided detailed comments on the operating environment or future outlook in the available content [5]. Other Important Information - The company is involved in various clinical trials and has multiple products in development, including those targeting specific biomarkers [3][4]. Q&A Session Summary Question: What is the guidance for 2026? - The company provided a revenue guidance of $148 million for 2025 and an estimated range of $200 million to $300 million for 2026 [6].

Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [4] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [4] - R&D expenses for 2025 were $148 million, lower than 2024 as many late-stage trials were nearing completion [4] Business Line Data and Key Metrics Changes - Ex-China FRUZAQLA sales grew by 26% year-over-year, totaling $366 million in in-market sales [2] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [2] - ORPATHYS and Surufatinib accounted for 11% of total 2025 EMARC sales but faced competition, impacting their performance [9] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds due to Medicare Part D redesign, impacting overall performance [8] - In China, ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [8] - The ITP market potential in China is significant, with over 250,000 actively treated patients, representing a market of $500 million to $700 million [18] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [3] - A focus on building a strong hematology portfolio is evident, with the launch of the first-in-class treatment for EZH2 mutation and follicular lymphoma [10] - The company is committed to maintaining a balance between R&D investments and commercial income generation [50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [24] - The oncology revenue guidance for 2026 is projected between $330 million and $450 million, reflecting strong growth expectations [5] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [70] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated investments in ATTC development [3] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong growth expectations, particularly from new indications and recovery momentum [28][29] Question: Why was the SAFFRON readout delayed? - The SAFFRON readout is now expected in mid-2026 [30] Question: What is the indication for the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2 expressing solid tumor patients, focusing on post-HER2 treatment settings [30] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that while there were impacts in 2025, they anticipate continued growth in the U.S. and other markets [70] Question: What is the strategy for the ATTC platform? - The company is considering potential licensing out of some programs while maintaining control over others to maximize long-term value [46]

Financial Data and Key Metrics Changes - Net sales increased over 17% year-over-year to nearly $136 million, reflecting strong performance [5][17] - EBITDA rose nearly 21% to $16.8 million, with adjusted EPS increasing from $0.03 to $0.08 [6][19] - Operating cash flow grew by more than $30 million year-over-year, reaching over $20 million in the quarter [6][19] - Gross margin improved by 210 basis points to 26.2%, driven by increased production volume and lower promotion costs [18] Business Line Data and Key Metrics Changes - Handgun unit shipments increased by 28%, while NICS data showed a decline of 2.2%, indicating market share growth [7][8] - Long gun shipments decreased by 25%, with NICS down 5.6%, attributed to prior year channel fill and product mix [8][9] - New products accounted for 44% of handgun shipments and 28% of long gun shipments, showcasing innovation's impact on sales [9] Market Data and Key Metrics Changes - Distributor inventory levels remained flat at approximately nine weeks of supply, indicating stable demand [12][17] - The overall market for firearms showed a stable environment, with expectations for continued strong demand [17][21] Company Strategy and Development Direction - The company is focused on innovation and maintaining pricing power, with a strategic emphasis on product development and market trends [5][16] - The Smith & Wesson Academy is exceeding expectations, contributing to growth in both consumer and law enforcement channels [13][14] - The company aims to reduce debt and strengthen its financial position, ending Q3 with $75 million in debt [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the brand's strength and product assortment, anticipating Q4 sales growth of 10%-12% over the previous year [21] - The company expects to see an increase in gross margin in Q4 due to higher production and demand [21] - Management highlighted a healthy pipeline for law enforcement sales, indicating a focus on this segment for future growth [33][34] Other Important Information - The company paid $5.8 million in dividends and ended the quarter with $23.5 million in cash and investments [20] - Capital spending for the year is expected to be between $25 million and $30 million [20] Q&A Session Summary Question: Recent pricing changes - Management confirmed a price increase of approximately 3% effective January 1, with no pushback from distributors or consumers [24][25] Question: Strength in handgun sales - Management attributed strong handgun sales to successful product refreshes and market trend alignment, particularly in the polymer pistol line [26][28] Question: Long gun market strategies - Management acknowledged challenges in the long gun market but noted potential opportunities in the hunting category and SBRs [29][30] Question: Law enforcement sales opportunities - Management emphasized the focus on law enforcement sales, highlighting a healthy pipeline and ongoing innovation in this area [32][34]